Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder

  • Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Arthritis license agreement

  • Major existing shareholders participated in the round

  • Proceeds to advance Imcyse's pipeline of first-in-class targeted disease modifying immunotherapeutics

Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced that it has concluded a Series B extension financing round, raising EUR 21.3 million (USD 25.8 million). Participants of the new round included existing investors, Biogenosis, Epimede, LSP, Noshaq, Société Régionale d'Investissement de Wallonie (SRIW), Société Fédérale de Participations et d'Investissement (SFPI) and KU Leuven. Pfizer Inc. (NYSE: PFE) also participated as Imcyse's newest investor taking an equity stake in the Company as part of the license agreement for Imcyse's Rheumatoid Arthritis (RA) program based on the Company's Imotope™ technology announced on February 3, 2021.

Denis Bedoret, Imcyse CEO , commented: "Completing this financing round reinforces the strength of the Company, allowing us to advance our programs to the next phase of development. Our aim is to be a major player in active specific immunotherapy. In this pursuit, we have taken our lead Imotope™ candidate into phase 2 for Type 1 Diabetes and have four other programs running in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Celiac Disease and Rheumatoid Arthritis. I would like to express our gratitude to our existing shareholders and to our new investor, Pfizer, for their support and confidence in our Imotope™ platform."

Proceeds from the latest financing round will be used to accelerate the advancement of several first-in-class targeted disease modifying immunotherapeutics, developing a robust and diverse clinical pipeline. In accordance with Imcyse's corporate strategy, the Company remains open to new partnerships and investors to further support its development and expansion into the U.S.

Imotope™ platform to prevent, stop and potentially cure autoimmune diseases

The Imcyse Imotope™ platform represents a next generation and potentially curative approach to severe autoimmune diseases for which there is no satisfactory therapy. Imotopes™ induce cytolytic T cells, which specifically eliminate the aberrant disease pathway while leaving the rest of the immune system unaffected. In addition to the Type 1 Diabetes program, its Multiple Sclerosis candidate is expected to commence clinical trials by 2022. In RA, Pfizer and Imcyse will collaborate to develop existing lead candidates and further optimize potential molecules. After a candidate is selected, Pfizer will lead clinical development and commercialisation activities.

Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company's unique technology platform allows it to specifically target immune cells involved in the destruction of the diseased organ. Disease specific Imotopes™, which are modified peptides, generate cytolytic CD4+ T-cells, that eliminate antigen-presenting cells and autoantigen specific lymphocytes. The Imotope™ effect, sustained over time, helps to prevent and treat diseases with no current curative alternative and to potentially cure patients without causing generalized immune suppression. The company has established proof of concept in several indications and has started a Phase 2 clinical program in type 1 diabetes with promising results already seen during the first Phase 1 trial. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases. Founded as a spin-off of the Catholic University of Leuven Imcyse subsequently relocated to Liège, Belgium.

Imcyse S.A.
Denis Bedoret
Chief Executive Officer

MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
teal and white pills over pink background

Top 10 Pharma Companies by Revenue (Updated 2023)

The pharmaceutical industry is the cornerstone of drug development, commercialization and marketing.

According to Statista, pharma sector revenues topped US$1 trillion for the first time in 2014, and has steadily increased since then to reach US$1.48 trillion in 2022. North America is the largest growth segment thanks to the behemoth US pharmaceutical industry. In terms of prescription drugs alone, Evaluate Pharma estimates that sales will reach US$1.6 trillion by 2028.

So which companies are responsible for the most growth and innovation in the pharma space?

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics

Keep reading...Show less

Jamieson Wellness Inc. Announces Voting Results from 2023 Annual and Special Meeting of Shareholders

Jamieson Wellness Inc. (" Jamieson Wellness " or the " Company ") (TSX: JWEL) announced today that each of the nominee directors listed in the management information circular of the Company dated March 23, 2023 was elected as a director of the Company (a " Director ") at the annual and special meeting (the " Meeting ") of the holders of common shares of the Company (the " Common Shares ") held today. The number of Common Shares voted in person or by proxy for the election of each Director or withheld was as indicated below:

Name of Nominee Votes For % Votes Withheld %
Heather Allen 30,622,518 85.85% 5,045,985 14.15%
Dr. Louis Aronne 31,463,170 88.21% 4,205,333 11.79%
Tania Clarke 32,027,820 89.79% 3,640,683 10.21%
Michael Pilato 32,057,068 89.88% 3,611,435 10.12%
Timothy Penner 31,761,670 89.05% 3,906,833 10.95%
Catherine Potechin 31,465,632 88.22% 4,202,871 11.78%
Mei Ye 32,024,954 89.78% 3,643,549 10.22%

Final results on all matters voted at the Meeting will be filed with the Canadian securities regulatory authorities and will be available on the Company's SEDAR profile at .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Jamieson Wellness Inc. Closes Previously Announced Partnership with DCP Capital

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that it has closed its previously announced agreement to partner with DCP Capital ("DCP") pursuant to which DCP has contributed $47.4 million ($35 million in USD) in capital in exchange for a 33% interest in the Company's Chinese operations. In conjunction with this investment, DCP has also completed its previously announced subscription for approximately $101.6 million ($75 million in USD) of preferred shares of the Company and warrants to purchase 2,527,121 common shares of the Company at an exercise price of $40.19. This represents a 10% premium to the 20-day volume weighted average common share price as of the signing of the subscription agreement on February 23, 2023.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global Therapeutic Head, Oncology, will represent the Company in a session scheduled at 4:20 p.m. (Eastern Time).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News